Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors (2023)
- Authors:
- USP affiliated authors: SCHEUCHER, PRISCILA SANTOS - FMRP ; TRAINA, FABÍOLA - FMRP ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; MELO, MANUELA ALBUQUERQUE DE - FMRP ; MACEDO, BRUNNO GILBERTO SANTOS DE - FMRP ; MARTINS, DIEGO ANTONIO PEREIRA - FMRP
- Unidades: FMRP; ICB
- DOI: 10.1182/blood-2023-190724
- Subjects: FARMACOLOGIA; HEMATOLOGIA; CÉLULAS MIELOIDES; LEUCEMIA MIELOIDE AGUDA; NEOPLASIAS POR TIPO HISTOLÓGICO; ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Publisher: American Society of Hematology
- Publisher place: Washington, DC
- Date published: 2023
- Source:
- Conference titles: 65th ASH Annual Meeting Abstracts
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
MELO, Manuela Albuquerque de et al. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors. Blood, v. 142, n. Supl. 1, p. 5752, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-190724. Acesso em: 30 abr. 2024. -
APA
Melo, M. A. de, Macedo, B. G. S., Fonseca, N. P., Scheucher, P. S., Martins, D. A. P., Traina, F., & Machado Neto, J. A. (2023). Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors. Blood, 142( Supl. 1), 5752. doi:10.1182/blood-2023-190724 -
NLM
Melo MA de, Macedo BGS, Fonseca NP, Scheucher PS, Martins DAP, Traina F, Machado Neto JA. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors [Internet]. Blood. 2023 ; 142( Supl. 1): 5752.[citado 2024 abr. 30 ] Available from: https://doi.org/10.1182/blood-2023-190724 -
Vancouver
Melo MA de, Macedo BGS, Fonseca NP, Scheucher PS, Martins DAP, Traina F, Machado Neto JA. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors [Internet]. Blood. 2023 ; 142( Supl. 1): 5752.[citado 2024 abr. 30 ] Available from: https://doi.org/10.1182/blood-2023-190724 - A inibição farmacológica de IRS1/2 induz apoptose em células BCR-ABL1 T315I
- IGF signaling predicts outcomes and is a promising target therapy for acute myeloid leukemia
- A ativação da via IGF1R prediz prognóstico e representa uma estratégia terapêutica em leucemia mieloide aguda
- The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms
- Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra
- Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models
- Stathmin 1 is highly expressed in acute promyelocytic leukemia and microtubule dynamics is a potential target for ATRA-resistant APL cells
- Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells
- DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients
- Stathmin 1 expression in plasma cell neoplasms. [Carta]
Informações sobre o DOI: 10.1182/blood-2023-190724 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
